Sevelamer Carbonate mMarkedly Reduces Levothyroxine Absorption.
We report a the case of a young woman affected by hypothyroidism due to Hashimoto's thyroiditis, previously well compensated with a full replacement therapy (150 mcg/day of levothyroxine), presenting a clinical picture of myxedema, with a TSH=650 mU/L. Two years before she had started a dialysis treatment because of a chronic renal failure and she had been treated for the last 18 months with sevelamer carbonate, a phosphate binder. No improvement of clinical conditions nor reduction in TSH serum levels were obtained by increasing the dose of levothyroxine up to 300 mcg/day, whereas the euthyroidism was finally restored by ...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - September 2, 2014 Category: Endocrinology Authors: Iovino M, Iovine N, Petrosino A, Giagulli VA, Licchelli B, Guastamacchia E, Triggiani V Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Use of sevelamer to examine the role of intraluminal phosphate in the pathogenesis of secondary hyperparathyroidism.
CONCLUSIONS: Phosphate influx affected [PTH] in CKD by determining [P]f in the CDN. In some patients, low calcium influx may have blunted the effect of sevelamer on [PTH].
PMID: 25079864 [PubMed - in process] (Source: Clinical Nephrology)
Source: Clinical Nephrology - August 4, 2014 Category: Urology & Nephrology Authors: Phelps KR, Stote KS, Mason D Tags: Clin Nephrol Source Type: research
Hyperphosphatemic familial tumoral calcinosis: Response to acetazolamide and postulated mechanisms
We report on a 7‐year‐old African American boy who presented with severe HFTC requiring numerous surgical excisions. Tumors continued to appear and others reoccurred despite phosphate restriction and sevelamer carbonate. At the age of 9.5 years, acetazolamide (40 mg/kg/day) was added and resulted in mild metabolic acidosis (bicarbonate 25.3 mEq/L vs. 21.4 mEq/L, P < 0.001; serum pH 7.38 vs. 7.31, P = 0.013, pre‐ and post‐acetazolamide, respectively) but no change in tubular reabsorption of phosphate (TRP) (96.9% vs. 95.9%, P = 0.34) or serum phosphate (6.6 mg/dl vs. 6.9 mg/dl, P = 0.52 ...
Source: American Journal of Medical Genetics Part A - March 25, 2014 Category: Genetics & Stem Cells Authors: Gal Finer, Heather E. Price, Richard M. Shore, Kenneth E. White, Craig B. Langman Tags: Clinical Report Source Type: research
Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study
Conclusions
This study demonstrated that hyperphosphataemia developed quickly following the cessation of phosphate binders and remained persistently elevated in end-stage CKD in the placebo-treated group. Gradually titrating up sevelamer carbonate from an initial dose of 2.4 g/day to an average daily dose of 7.1 ± 2.5 g/day was well tolerated, safe and efficacious in contemporary Chinese haemodialysis patients. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - January 10, 2014 Category: Urology & Nephrology Authors: Chen, N., Wu, X., Ding, X., Mei, C., Fu, P., Jiang, G., Li, X., Chen, J., Liu, B., La, Y., Hou, F., Ni, Z., Fu, J., Xing, C., Yu, X., Huang, C., Zuo, L., Wang, L., Hunter, J., Dillon, M., Plone, M., Neylan, J. Tags: Chronic Kidney Disease Source Type: research
Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders
In conclusion, these two noncalcium-containing phosphate-binding agents showed a differential effect on gastrointestinal calcium absorption. These findings may help to improve the management of calcium balance in patients with renal failure, including concomitant use of vitamin D. (Source: AJP: Renal Physiology)
Source: AJP: Renal Physiology - January 1, 2014 Category: Urology & Nephrology Authors: Behets, G. J., Dams, G., Damment, S. J., Martin, P., De Broe, M. E., D'Haese, P. C. Tags: ARTICLES Source Type: research
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease
Endothelial dysfunction underlies multiple cardiovascular consequences of chronic kidney disease (CKD) and antecedent diabetes or hypertension. Endothelial insults in CKD or end-stage renal disease (ESRD) patients include uremic toxins, serum uric acid, hyperphosphatemia, reactive oxygen species, and advanced glycation endproducts (AGEs). Sevelamer carbonate, a calcium-free intestinally nonabsorbed polymer, is approved for hyperphosphatemic dialysis patients in the US and hyperphosphatemic stage 3–5 CKD patients in many other countries. Sevelamer has been observed investigationally to reduce absorption of AGEs, bacte...
Source: Therapeutic Advances in Cardiovascular Disease - December 10, 2013 Category: Cardiology Authors: Rastogi, A. Tags: Review Source Type: research
Differences in gastrointestinal calcium absorption after ingestion of calcium-free phosphate binders.
In conclusion, these two non calcium-containing phosphate binding agents showed a differential effect on gastrointestinal calcium absorption. These findings may help to improve management of calcium balance in patients with renal failure, including concomitant use of vitamin D.
PMID: 24197066 [PubMed - as supplied by publisher] (Source: Am J Physiol Renal P...)
Source: Am J Physiol Renal P... - November 6, 2013 Category: Urology & Nephrology Authors: Behets GJ, Dams G, Damment SJ, Martin P, De Broe ME, D'Haese PC Tags: Am J Physiol Renal Physiol Source Type: research
Epicardial adipose tissue predicts mortality in incident hemodialysis patients: a substudy of the Renagel in New Dialysis trial
Conclusions
In this subanalysis of a randomized trial, EAT was an independent predictor of mortality in incident hemodialysis patients after ~4 years of follow-up. These hypothesis-generating findings will need confirmatory evidence. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - September 27, 2013 Category: Transplant Surgery Authors: D'Marco, L. G., Bellasi, A., Kim, S., Chen, Z., Block, G. A., Raggi, P. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research
A regenerable potassium and phosphate sorbent system to enhance dialysis efficacy and device portability: an in vitro study
Conclusion
RES-A and FeOOH are suitable, regenerizable sorbents for potassium and phosphate removal in dialysate regeneration. Use of zirconium carbonate and ZIR-hydr may further increase phosphate adsorption, but may compromise sorbent regenerability. Use of polymeric amines for phosphate adsorption may enhance sorbent regenerability. Calcium and magnesium preloading considerably reduced net adsorption of these ions. (Source: Nephrology Dialysis Transplantation)
Source: Nephrology Dialysis Transplantation - September 11, 2013 Category: Urology & Nephrology Authors: Wester, M., Simonis, F., Gerritsen, K. G., Boer, W. H., Wodzig, W. K., Kooman, J. P., Joles, J. A. Tags: Intra- and Extracorporeal Treatments of Kidney Failure Source Type: research
Comparison of sevelamer and calcium carbonate on endothelial function and inflammation in patients on peritoneal dialysis
ConclusionsTreatment with sevelamer carbonate has beneficial effects compared with calcium carbonate in decreasing inflammation and improving EF in patients with T2DM on PD. (Source: Journal of Renal Care)
Source: Journal of Renal Care - March 1, 2013 Category: Urology & Nephrology Authors: Sudha P. Chennasamudram, Tanjila Noor, Tetyana L. Vasylyeva Tags: Original Research Source Type: research
